{"id":"NCT02688556","sponsor":"Sun Pharmaceutical Industries Limited","briefTitle":"Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca","officialTitle":"A Randomized, Multicenter, Double-Masked, Vehicle-Controlled Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-02","primaryCompletion":"2016-11","completion":"2016-12","firstPosted":"2016-02-23","resultsPosted":"2019-04-08","lastUpdate":"2022-08-29"},"enrollment":745,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Keratoconjunctivitis Sicca"],"interventions":[{"type":"DRUG","name":"cyclosporine","otherNames":["Seciera"]},{"type":"DRUG","name":"vehicle of OTX-101","otherNames":[]}],"arms":[{"label":"OTX-101 0.09%","type":"EXPERIMENTAL"},{"label":"Vehicle","type":"PLACEBO_COMPARATOR"}],"summary":"This is a randomized, double-masked, vehicle-controlled study of the safety and efficacy of OTX-101 (0.09% cyclosporine nanomicellar solution) in the treatment of keratoconjunctivitis sicca to be conducted at approximately 50 sites.","primaryOutcome":{"measure":"Tear Production","timeFrame":"Baseline and 12 weeks","effectByArm":[{"arm":"OTX-101 0.09%","deltaMin":16.6,"sd":null},{"arm":"Vehicle","deltaMin":9.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":11},"locations":{"siteCount":3,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":372},"commonTop":["Instillation site pain","Conjunctival hyperaemia","Sinusitis","Eye irritation","Headache"]}}